Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
NEW YORK, March 13, 2018 --
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 19, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
